Supplementary Figure 1:
Reoxygenation-conditioned medium (RCM; 50 g/ml) phosphorylates ERK1/2, SAPKs, p38MAPK in cultured rat cardiac myocytes. The procedures for Western analysis were as described previously 9 . The experiments were performed at least in triplicate. The results shown are from one representative experiment.
Supplementary Figure 2:
Reoxygenation-conditioned media (RCM)-induced apoptosis of cultured rat cardiac myocytes as determined by TUNEL staining (brown) and cardiac myosin immunostaining (blue) . Cardiac myocytes at 72 h after addition of RCM (total protein concentrations; b, 25 g/ml; c, 50 g/ml; d, 100 g/ml, respectively) and without RCM (a). Higher magnification revealed granule-like brown TUNEL-stainings (arrows) in almost all round-shaped cardiac myocytes (e). RCM induced apoptosis of cardiac myocytes dose-dependently (f). At least 800 cells were counted in each group (mean ± s.e.m., n=4 for each)
Supplementary Figure 3:
Western analysis of Myc-tagged-cytosolic and FLAGtagged-secreted recombinant eIF5A proteins. Myc-and His-tagged cytosolic-reeIF5A protein and FLAG-and His-tagged secreted-re-eIF5A protein were mixed and subjected to a 2-D gel electrophoresis, and analyzed by Western blot, first with anti-Myc mAb developed by chemiluminescence using alkalinephosphatase, and then, with anti-FLAG mAb developed by immunostaining using horseradish peroxidase (HRP). Arrows indicate A and A', unhypusinated; B and B', deoxyhypusinated; C and C', hypusinated form, respectively. 
Supplementary

Supplementary Figure 5:
Expression of eIF5A in myocardial tissues subjected to ischemia/reperfusion in vivo. Immunofluorescence localization of eIF5A protein in myocardial tissues from sham-operated rats and rats subjected to myocardial ischemia/reperfusion in vivo. The procedures for myocardial ischemia/reperfusion were as described elsewhere 36 .
Supplementary Figure 6:
Secreted-re-eIF5A (10 g/ml) induced phosphorylation of ERK1/2, SAPKs , p38MAPK, IB, and ATF2 in cultured rat cardiac myocytes. The procedures for Western analysis were as described previously 9 . The experiments were performed at least in triplicate. The results shown are from one representative experiment.
Supplementary Figure 7:
Effects of secreted re-eIF5A (10 g/ml) on phosphokinase activation in human skeletal muscle myoblasts (ZenBio, Inc.). Cell lysates were applied to Human Phospho-Kinase Array (R & D Systems, Inc.; according to the manufacturer's instructions).
Supplementary Figure 8:
Secreted re-eIF5A increased phosphorylation of ATM and p53. (a) Secreted re-eIF5A (10 g/ml) increased phosphorylation of ATM at Ser1981 (10H11.E12; Cell Signaling Technology) and p53 at Ser15 (#9284; Cell Signaling) and Ser20 (sc-18078; Santa Cruz), but not Ser46 (ab76242; Abcam). The experiments were performed at least in triplicate. The results shown are from one representative experiment. Control antibodies were used for ATM (sc-7230; Santa Cruz) and p53 (sc-55476; Santa Cruz). (b) and (c) Effects of a specific p53 inhibitor, pifithrin-30 M, pretreated for 24 h) on apoptosis induction of cardiac myocytes by secreted re-eIF5A (10 g/ml, 48 h) as determined by TUNEL staining (brown) and cardiac myosin immunostaining (blue) as in Fig. 3a . * P <0.0001 vs. secreted re-eIF5A only (mean ± s.e.m., n=4 for each) (Dunnett's multiple comparison test).
Supplementary Figure 9: Effects of PARP-1 inhibitor (3-aminobenzamide [Sigma], 2 mM) or caspase inhibitor (Z-VAD.fmk [BIOMOL International, LP],
100 M), added 1 h before addition of secreted-re-eIF5A (10 g/ml), on the induction of apoptosis in cardiac myocytes. (a) TUNEL staining (brown) and cardiac myosin immunostaining (blue) as in Fig. 3a . Representative images at 72 h after addition of secreted-re-eIF5A. (b) The percentage of apoptotic cardiac myocytes determined by TUNEL staining at 72 h after addition of secreted reeIF5A. Data are expressed as (mean ± s.e.m., n=4 for each). *P < 0.0001 vs. secreted re-eIF5A only (Dunnett's multiple comparison test).
Supplementary Figure 10:
Effects of neutralization with anti-eIF5A mAbs (0.02 mg/ml) on hypoxia (60 min)/reoxygenation (15 min)-induced activation of ERK1/2 in cultured cardiac myocytes. * P <0.001 vs. Unstimulated ** P <0.01 and *** P <0.05 vs. mouse IgG (mean ± s.e.m., n=4 for each) (Dunnett's multiple comparison test).
Supplementary Figure 11:
Effects of neutralization with anti-eIF5A mAbs (0.02 mg/ml) on hypoxia (11 h)/reoxygenation (48 h)-induced cytosolic release of cytochrome c (a) as well as caspase-3 activation (b) in cultured cardiac myocytes. (a) * P <0.0002 vs. Unstimulated ** P <0.0002 and *** P <0.0005 vs. mouse IgG (mean ± s.e.m., n=4 each). (b) * P <0.0001 vs. Unstimulated ** P <0.001 vs. mouse IgG (mean ± s.e.m., n=4 for each) (Dunnett's multiple comparison test).
Supplementary Figure 12:
Effects of neutralization with anti-eIF5A mAbs (0.02 mg/ml) on hypoxia (15 h)/reoxygenation (72 h)-induced apoptosis induction in cultured cardiac myocytes. (a) TUNEL staining (brown) and cardiac myosin immunostaining (blue) as in Fig. 3a . Representative images at 72 h after reoxygenation. (b) The percentage of apoptotic cardiac myocytes determined by TUNEL staining at 72 h after reoxygenation.
* P <0.0001 vs. Unstimulated ** P <0.0001 and *** P <0.001 vs. Mouse IgG (mean ± s.e.m., n=4 for each) (Dunnett's multiple comparison test). with YSPN2-74-18 (20 g/ml) as a capture antibody fixed on the wells of microtiter strips. Plasma samples and standards of known human re-eIF5A were pipetted into the wells and incubated. After washing, horseradish peroxydase (HRP)-labeled YSP5-45-36 (1 g/ml) was added as a detection antibody and incubated. After washing, color development was carried by addition of a substrate solution. Values are means ± s.d., (n=4).
